# Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
**AGENCY:**
National Institutes of Health, HHS.
**ACTION:**
Notice; correction.
**SUMMARY:**
The Department of Health and Human Services, National Institutes of Health published a Notice in the *Federal Register* on August 5, 2025. That notice requires a correction in the *SUPPLEMENTARY INFORMATION* section.
**DATES:**
Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 9, 2026 will be considered.
**ADDRESSES:**
Inquiries and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240)-276-5484; Email: *[email protected].*
**SUPPLEMENTARY INFORMATION:**
**Correction**
In the *Federal Register* of February 13, 2026, in FR Doc. 2026-02907, on page 6864, as found within the *SUPPLEMENTARY INFORMATION* section. Currently reads:
“The development, production, and commercialization of an anti-CD19 targeting chimeric antigen receptor (CAR)-based immunotherapy using a:
1. non-viral synthetic nanoparticle-based system, or
2. viral system (excluding lentiviral)
that encapsulates mRNA or DNA encoding a CAR having the complementary determining region (CDR) sequences of the anti-CD19 scFv known as Hu19, for the treatment or prevention of autoimmune diseases. And is corrected to read:
“The development, production, and commercialization of an anti-CD19 targeting chimeric antigen receptor (CAR)-based immunotherapy using a:
3. non-viral synthetic nanoparticle-based system, or
4. viral system
that encapsulates mRNA or DNA encoding a CAR having the complementary determining region (CDR) sequences of the anti-CD19 scFv known as Hu19, for the treatment or prevention of autoimmune diseases.
Alycia Booth,
NIH Federal Register Certifying Official, National Institutes of Health.